Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data
Portfolio Pulse from Vandana Singh
Amgen Inc (NASDAQ:AMGN) has published promising early-stage data on its experimental obesity drug, AMG 133 (maridebart cafraglutide), in Nature Metabolism. The drug demonstrated significant weight loss and an acceptable safety profile in animal and early human trials. A Phase 2 study has completed enrollment, with results expected in late 2024. AMGN shares rose 1.26% to $327.28.
February 05, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen Inc's experimental obesity drug, AMG 133, has shown promising early-stage results, leading to a 1.26% increase in its stock price to $327.28.
The positive early-stage data of AMG 133 suggests a strong potential for Amgen in the obesity treatment market, which is likely to generate investor optimism and drive the stock price up in the short term. The completion of Phase 2 enrollment and anticipation of results in late 2024 further support the potential impact on Amgen's stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100